TCGA-77-8146-01A-11R-2247-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.420
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- APICAL_JUNCTION+0.380
- GLYCOLYSIS+0.350
- COAGULATION+0.340
- HEDGEHOG_SIGNALING+0.340
- HYPOXIA+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- APICAL_SURFACE+0.330
- WNT_BETA_CATENIN_SIGNALING+0.320
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.550
- INTERFERON_GAMMA_RESPONSE-0.390
- OXIDATIVE_PHOSPHORYLATION-0.360
- PROTEIN_SECRETION-0.310
- MYC_TARGETS_V1-0.270
- MYC_TARGETS_V2-0.200
- PANCREAS_BETA_CELLS-0.190
- UNFOLDED_PROTEIN_RESPONSE-0.190
- ALLOGRAFT_REJECTION-0.180
- SPERMATOGENESIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-56-8308-01A-11R-2296-07 | — | cohortSQ2 | 0.817 |
| 2 | R211 | — | — | 0.815 |
| 3 | SRR8613758 | — | C | 0.784 |
| 4 | 20040086.TNBC | — | C | 0.778 |
| 5 | TCGA-56-5898-01A-11R-1635-07 | — | cohortSQ1 | 0.776 |
| 6 | C3N-02289 | — | cohortSQ1 | 0.770 |
| 7 | SRR9879274 | — | cohortSQ1 | 0.770 |
| 8 | SRR8613716 | — | C | 0.767 |
| 9 | C3N-02285 | — | cohortSQ1 | 0.761 |
| 10 | SRR8943050 | — | — | 0.755 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.380 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.340 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.280 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.270 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |